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ABSTRACT
Aneuploidy, the unbalanced number of chromosomes in a cell, is considered 
a prevalent form of genetic instability and is largely acknowledged as a condition 
implicated in tumorigenesis. Epigenetic alterations like DNA hypomethylation have 
been correlated with cancer initiation/progression. Furthermore, a growing body of 
evidence suggests the involvement of epigenome-wide disruption as a cause of global 
DNA hypomethylation in aneuploidy generation. 
Here, we report that the DNA hypomethylating drug 5-aza-2’-deoxycytidine 
(DAC), affects the correct ploidy of nearly diploid HCT-116 human cells by altering 
the methylation pattern of the chromosomes. Specifically, we show that a DAC-
induced reduction of 5-Methyl Cytosine at the pericentromeric region of chromosomes 
correlates with aneuploidy and mitotic defects.
Our results suggest that DNA hypomethylation leads to aneuploidy by altering 
the DNA methylation landscape at the centromere that is necessary to ensure proper 
chromosomes segregation by recruiting the proteins necessary to build up a functional 
kinetochore.
INTRODUCTION
The majority of human tumours show a form 
of genome instability called chromosomal instability 
(CIN) that refers to the high rate of numerical and 
structural chromosome aberrations found in cancer cells. 
Numerical CIN is characterised by gain and loss of 
whole chromosomes resulting in aneuploidy, a harmful 
condition for the viability of cells and organisms. 
At the molecular level, aneuploidy arises by several 
mechanism(s) including mutations in genes encoding 
mitotic regulators [1, 2], tumour suppressors or controlling 
centrosome numbers [3-7], altered expression of mitotic 
checkpoint proteins, defects in chromatid cohesion and in 
kinetochore-microtubule attachment [6-10]. Furthermore, 
epigenetic alterations such as DNA hypomethylation 
are considered as a cause of aneuploidy [11, 12]. Global 
genome hypomethylation has been described in breast, 
ovarian, cervical and brain tumours and it has been 
reported that severe hypomethylation correlates with 
increased malignancy [13]. However, little is known 
about the mechanism(s) by which most of human cancers 
become aneuploid following DNA hypomethylation. DNA 
hypomethylation can result in different phenotypic effects 
depending on the cell genotype. Previously, we reported 
that DNA Methyl-Transferase 1 (DNMT1) depletion 
caused cell cycle arrest in IMR90 cells and aneuploidy 
in HCT-116 colon cancer cells missing p14ARF function 
in association with global DNA hypomethylation 
[14]. Loss of DNMTs function leads to global genome 
hypomethylation and to chromosomal instability in 
mouse models [15] and human ICF syndrome [16, 17]. 
Specifically, cells from patients with ICF syndrome exhibit 
hypomethylation of pericentromeric regions associated 
with the formation of micronuclei [18]. 
Two different hypotheses, not mutually exclusive, 
have been formulated to explain the correlation 
between DNA hypomethylation and aneuploidy. 
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DNA hypomethylation could alter the expression of 
genes coding for specific mitotic checkpoint proteins. 
Alternatively modifications of chromosomal DNA 
methylation pattern could also interfere with the correct 
structure of chromosomes [12]. In this regard, it has 
been reported that an epigenetic, sequence-independent 
mechanism underlies the formation of the centromere 
[19, 20]. Indeed, the epigenetic environment onto and 
around the centromere is very important to ensure proper 
chromosome segregation. In all species studied, the 
centromere is defined by a specific chromatin domain 
containing a H3 histone variant (CENP-A), flanked 
by a large pericentromeric heterochromatin domain 
CENP-A free and enriched in highly repetitive α-satellite 
sequences. Although repetitive DNA sequences are not 
essential for centromere formation, they provide the 
necessary environment to assemble the centromere [21 
22] and the disruption of pericentromeric heterochromatin 
conformation leads to chromosome segregation defects, 
generally associated with the loss of cohesins into and 
around this domain [20, 23, 24].
The decrease of pericentromeric methylation in 
human lymphocytes treated with the 5-Azacytidine (AZA) 
inducing loss of DNA methylation was associated with 
missegregation of chromosomes 1 and 16 [25]. Given that 
these two chromosomes have highly methylated satellite 
2 regions this observation suggests a relationship between 
loss of DNA methylation and chromosomes loss. 
To investigate the role of global DNA 
hypomethylation on chromosome structure and 
segregation and to clarify the relationship between DNA 
hypomethylation and generation of aneuploidy, we treated 
HCT-116 cells, a nearly diploid human cell line with 
5-aza-2’-deoxycytidine (DAC, also known as decitabine), 
to induce DNA hypomethylation [26]. After cellular 
uptake and phosphorylations, the cytidine analogue AZA 
is incorporated into both DNA and RNA with effects 
on the processing of tRNA and thereby interfering with 
protein translation. On the contrary, DAC is incorporated 
into DNA and causes more efficient inhibition of DNA 
methyltransferases [27]. DAC acts through the formation 
of covalent DNMT1-DAC-DNA adducts leading to 
a decrease in DNMT1 levels and CpG dinucleotides 
hypomethylation [28]. This in turn causes changes in the 
genome methylation pattern to be transmitted to daughter 
cells.
Here, we report that the DNA hypomethylating drug 
5-aza-2’-deoxycytidine (DAC), affects the correct ploidy 
of nearly diploid HCT-116 human cells by altering the 
methylation pattern of the chromosomes. Specifically, we 
show that a DAC-induced reduction of 5-Methyl Cytosine 
at the pericentromeric region of chromosomes correlates 
with aneuploidy and mitotic defects
RESULTS
Low doses of DAC induce DNA hypomethylation 
and aneuploidy
DNA methylation occurs onto cytosine located in the 
so-called CpG islands thanks to DNA methyl-transferases. 
DNA methylation strongly influences chromatin structure 
and generally leads to a higher degree of compaction thus 
repressing gene expression. In order to study the effects of 
DNA hypomethylation on chromosome dynamics, we first 
assessed at which concentration DAC was able to induce 
DNA hypomethylation without affecting cell viability and 
cell proliferation. HCT-116 cells were treated with DAC at 
different doses and the effects of exposure were evaluated 
over a period of 72 hours. Cells treated with 2 µM and 
5µM of DAC did not show reduction of cell viability 
(Figure 1A). In addition the acridine orange assay showed 
that HCT116 cells after DAC treatment did not undergo 
apoptosis or necrosis (Figure 1B). On the contrary, 
DAC at a concentration of 10 µM severely impaired 
cell viability (Figure 1A). Next, we assessed the level of 
5-methylcytosine (5mC) in HCT-116 cells after the DAC 
treatment. Fluorescence microscopy and Slot-blot analysis 
showed a progressive and intensive reduction of the 5-mC 
signal throughout 72 hours of treatment with a decrease of 
50%, 60% and 80% after 24, 48 and 72 hours, respectively 
(Figure 2A, 2B; Figure S1). This result is in accordance 
with the DAC mechanism affecting DNA methylation 
level via CpG dinucleotides hypomethylation [28] that in 
turn causes changes in the genome methylation pattern of 
daughter cells. To determine if loss of methylation upon 
DAC treatment occurred also at specific hypermethylated 
promoter we evaluated the promoter methylation status 
of the CHFR gene that is hypermethylated in HCT-116 
cells [29]. The methylation status of the CHFR promoter 
was assessed by Methylation Specific PCR (MSP) in 
HCT-116 cells treated with DAC (1, 2, 5μM) for 72 hours. 
DAC treatment induced loss of DNA methylation of the 
CHFR gene promoter as revealed by the presence of an 
amplicon obtained with specific primers annealing with 
the unmethylated DNA (Figure 2C). The methylation loss 
of CHFR promoter was confirmed by the re-expression 
of CHFR assessed by RT-PCR and Western Blot (Figure 
2D, 2E).
As loss of DNA methylation could interfere with 
chromosome dynamics, we evaluated if the global DNA 
hypomethylation observed upon the DAC treatment was 
associated with aneuploidy. We scored the number of 
chromosomes/cell by fluorescent microscopy in HCT-116 
cells treated for 72 hours with 5µM DAC. This analysis 
showed a significant alteration in the distribution of the 
number of chromosomes per cell after treatment with 
DAC when compared to the control. Specifically, after 
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24 hours of treatment we observed a 30% reduction 
in the number of cells with 45 chromosomes and 
concurrently a significant increase in aneuploid cells with 
a clear trend to hypodiploidy. Additionally, it was also 
observed a significant increase of hypodiploid cells (<39 
chromosomes per cell) at 48 and 72 hours, ranging from 
15% to 25 % respectively (Figure 3).
DAC treatment induces abnormal chromosomal 
DNA methylation pattern
Recently, it has been proposed a relationship 
between loss of DNA methylation and chromosome 
segregation defects through the disruption of 
pericentromeric heterochromatin configuration [20, 23] 
[24, 25]. Given the increase in the number of aneuploid 
cells upon DAC treatment, we aimed to evaluate the 
changes in the methylation pattern of chromosomes by 
immunofluorescence microscopy to establish whether 
these changes could account for the mitotic segregation 
defects described. After 24 hours of DAC treatment, 
we did not observe a different 5-mC-FITC labelling of 
chromosomes in respect to untreated cells. However, 
after 48 hours chromosomes appeared asymmetrically 
labelled with one chromatid of each chromosome 
unlabelled (Figure 4). Moreover, pericentromeric regions 
appeared faintly labelled or not labelled at all (Figure 
4B, e). The asymmetric methylation of sister chromatids 
is in agreement with data shown in Figure 2A and is 
indicative of loss of DNA methylation occurring after 
two subsequent cell cycles in presence of DAC. To relate 
the observed chromosome methylation pattern to the 
number of cell divisions that HCT116 cells underwent 
in the presence of DAC we determined cell proliferation 
timing by allowing cells to incorporate the halogenated 
thymidine analog 5-bromodeoxyuridine (BrdU) into 
DNA. Subsequently, by bivariate DNA-BrdU (propidium 
Figure1: Effects of DAC on viability of HCT-116 cells. A. Bar graph showing the viability of HCT-116 treated with different DAC 
concentrations (2, 5 and 10 μM) at different times (24h, 48h and 72h), A treatment with only vehicle (+DMSO) and a no-treated sample 
(-DMSO) are included as controls. The statistics was performed applying the ANOVA test with Bonferroni correction ** (P<0.01; n=3). B. 
Histogram showing the values (%) of living and dead cells stained with Acridine Orange/Etidium Bromide (AO/EB) after DAC treatment 
at different concentrations and times (24, 48 and 72h). C. Images of the different cell populations after AO/EB staining observed with 
fluorescence microscopy. Living cells appear green, dead cells red.
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Figure 2: Low doses of DAC induce DNA de-methylation. A, immunofluorescence microscopy was performed to detect 5-mC 
signals in HCT-116 nuclei after treatment with 5 µM DAC for 24-, 48- and 72 h. A. DMSO treatment was included as control. B. slot-blot 
analysis detecting 5-mC in DAC treated HCT-116 cells (0h-72h, top right panel). The amount of spotted DNA was detected by methylene 
blue staining (bottom right panel). The values vs control ± SEM are indicated under the panel. The left panel shows the non-methylated 
DNA of Escherichia coli ET12567/pUZ8002 used as a negative control (1), and the methylated DNA of Escherichia coli Yale BW25113 
used as a positive control (2). Data are from three independent experiments. C. Methylation Specific PCR shows the methylation status of 
the CHFR gene promoter in HCT-116 cells treated with 1, 2 and 5µM DAC for 72h (lanes 3, 4, 5, respectively). The “M-CHFR” and the 
“U-CHFR” panels show amplification products obtained by using primers for methylated and unmethylated CHFR promoter, respectively. 
SW480 (1) and HCT-116 cells (2) were used as negative and positive control in M-CHFR panel, the opposite HCT-116 (1) and SW480 (2) 
in the U-CHFR panel. Lane 6 is no template. D. RT-PCR showing expression levels of CHFR in HCT116 untreated (lane 1) and treated 
with DAC (5µM) for 24h (lane 2) or 48h (lane 3). GAPDH was used as an internal control. E. Western Blot showing the presence of CHFR 
protein in HCT116 cells after 48 hours of treatment with DAC 5µM (lane 2) in respect to HCT116 left untreated (lane 1). β-tubulin was 
used as a loading control.
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iodide (PI) and fluorescein isothiocyanate (FITC)) flow 
cytometry we analysed the presence of the BrdU-labeled 
cells during the cell cycle. The nuclei stained with PI, 
which fluoresces red at an intensity reflecting the DNA 
content, define a reference for G1 and G2/M cells. The 
cytofluorimetric profiles of HCT16 cells treated with DAC 
or left untreated were similar and suggest that HCT116 
DAC treated cells duplicate in about 24 hours (Figure S2).
We gained additional evidence that DAC treated 
HCT116 cells have undergone two cell cycles using 
the Fluorescence plus Giemsa (FPG) technique to stain 
chromosomes. The FPG method is generally used to 
visualize sister chromatid exchanges in cells grown for 
two cell cycles in BrdUrd [30]. Based on semiconservative 
DNA replication, both chromatids of a chromosome will 
have incorporated BrdU into either one or both of their 
strands at the end of two cycles. After staining with 
the DNA-binding fluorochrome Hoechst 33258, UV 
photolysis, and Giemsa staining, the doubly substituted 
chromatids (new strands) appear light and the sister 
chromatids (parental strands) appear dark when observed 
by transmitted light microscopy (Figure S2B). 
All together these findings confirm that the presence 
of asymmetrically methylated sister chromatids (Figure4) 
is explained by the semiconservative DNA replication 
coupled with the passive loss of CpG dinucleotide 
methylation caused by DAC exposure (48h). 
In the attempt to understand how the induced 
DNA hypomethylation triggered aneuploidy, we looked 
at the morphology of chromosomes. In addition to 
Figure 3: DAC induces aneuploidy in HCT-116 cells. Histogram of Ploidy data of HCT-116 cells untreated or treated with 5µM 
DAC for 24 h (n=56), 48 h (n=68) and 72 h (n=64). The data are plotted as relative frequency of the number of chromosomes per cell and 
are expressed as a percentage. (n= Number of methaphases analysed per sample; data are from 3 independent experiments). 
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chromosomal aberrations such as chromatid breaks/gaps, 
chromatid exchanges and chromosome pulverization 
(Figure S3, S4), we found “railroad track” chromosomes 
(RR) characterised by the absence of a clear centromere 
in 15% of mitosis analised. RR chromosomes coexisted 
with normal chromosomes in the same metaphase spread 
(Figure 5). Chromosomes in mitosis were DAPI stained 
to visualize the lack of a centromere with a plot-profiler 
method (Figure 5B). 
Figure 4: DAC alters the DNA methylation pattern of chromosomes. A, immunofluorescence analysis shows the distribution 
of 5-mC on mitotic chromosomes. HCT-116 cells untreated or DAC-treated for 24 or 48h were stained using an anti- 5-mC monoclonal 
antibody conjugated to FITC (green signal), chromosomes were stained with DAPI (blue). Scale bars represent 10 µm. B. Magnified view 
of the chromosomes marked in A. with a yellow arrow. These chromosomes were chosen to perform a plot profiler analysis: chromosomes 
a and b for the control sample, c and d for the 24 h treatment sample and e and f for 48h treatment. The graphs were realised plotting the 
fluorescent intensity values (y-axis, arbitrary units) against the length of the scan (-axis) and show the DAPI profile (blue curve) and the 
distribution of methylation (green curve). Scale bar: 5 µm. 
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Extended DAC treatment causes aneuploidy and 
chromosome abnormalities
We addressed then the question if an extended DAC 
treatment, up to 2 weeks, at lower doses than 5µM could 
have a different impact on cell viability and ploidy. Cells 
were then treated with 2µM DAC and counted every 
24 hours to estimate the proliferation rate that resulted 
slightly delayed in respect to untreated cells (Figure 6A). 
In addition, the cellular ploidy was assessed after one week 
of treatment by using the ‘modfit’ software that estimates 
the ploidy of the cells after FACS analysis by measuring 
the DNA content (Propidium Iodide fluorescence). The 
results indicated the presence of an elevated percentage 
of aneuploid cells (50%) in these treated cells (Figure 6C).
We determined then the effects of 2µM DAC 
treatment on aneuploidy generation at different times 
by evaluating chromosome numbers at 72 hours, 1 
week, 10 days and 2 weeks from the beginning of the 
treatment. Seventy-two hours post-treatment cells 
showed aneuploidy and in particular 23% of aneuploidy 
cells were hypodiploid in which only few chromosomes 
were missing. This percentage increased up to 40% and 
remained stable up to two 2 weeks of treatment (Figure 
7A). The prolonged treatment with 2µM of DAC also 
induced RR chromosomes (Figure 7B; Figure S5). These 
aberrant chromosomes were mainly evident after one 
week of treatment when the about 70% of metaphases 
showed at least a couple of RR chromosomes in which the 
centromere appeared less Giemsa stained. Taken together 
these experiments showed that DNA hypomethylation 
caused by DAC treatments induced in addition to 
aneuploidy, alteration of chromosome methylation pattern 
and of cell division. To establish whether the effects of 
the DAC treatment were reversible, cells exposed to 2µM 
DAC for one week were released in DAC-free medium for 
Figure 5: DAC induces “railroad track” chromosomes (RR). A. representative images of metaphases of untreated or DAC-treated 
HCT-116 cells. RR chromosomes were observed and a magnification is shown in the inset. Cells were stained with DAPI (in the inset is 
shown a magnification). Scale bars represent20 μm. B. DAPI signal intensity profile. The interchromatidic distance at the centromere was 
measured and the graph was realised plotting the distance in pixels of chromosome long axis in the x-axis and the pixel intensities along the 
chromosome short axis in the y-axis. The chromosomes analysed were selected from the metaphases shown in (A) (coloured circles) and 
are indicated in the plot by different coloured lines; y-axis: 
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additional 14-20 days. After the release from the drug we 
observed a decrease in the number of aneuploid cells as 
well as of RR chromosomes suggesting that the effect of 
the DAC were partially reversible (Figure 7C).
Aneuploidy triggered by hypomethylation is 
associated with mitotic defects 
We investigated if the altered methylation pattern of 
chromosomes correlated with chromosomes segregation 
defects. To this purpose, we performed live-imaging of 
DAC-treated HCT-116 cells expressing H2B-GFP [31] to 
detect mitotic abnormalities from which aneuploidy could 
arise. At 24 and 48 hours after DAC treatment (5µM), 
we observed increased mitotic defects and chromosome 
alterations like: chromosome bridge, lagging chromosome, 
micronuclei and chromosome out of the spindle. (Figure 
8, S4, Table 1). We noticed a strong increase (>40%) of 
these mitotic alterations at 48 hours from DAC treatment 
in agreement with the observed aneuploidy (Figure 3). The 
delay from prometaphase to anaphase progression was 
likely caused by the presence of these defects (Figure 8B).
Figure 6: Extended treatment with DAC leads to 
aneuploidy. A. Proliferation rates of HCT-116 cells treated 
with 2uM DAC B., C. Flow cytometry analysis shows cell cycle 
distribution of HCT-116 cells untreated or treated for one week 
with 2µM DAC. The flow cytometry data were analysed using 
the ModFit software.
Figure 7: Prolonged DAC treatment causes aneuploidy 
and railroad track chromosomes. A. The histogram 
relative to the ploidy of HCT-116 cells untreated or treated with 
2µM DAC for the indicated period of time is shown in. B. the 
histogram shows the percentage of HCT-116 cells with railroad 
track chromosomes (x axis). Cells were treated with 2µM DAC 
for one and two weeks and released for two additional weeks. 
C. the histogram shows the percentage of aneuploid and diploid 
metaphases of HCT-116 cells treated with 2µM DAC and 
released (rel.) for the indicated times.
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DISCUSSION 
Epigenetic marks combine to bring about 
DNA hypercondensation typical of centromeric and 
pericentromeric heterochromatin [32, 20, 22]. The 
maintenance of the epigenetic memory at these regions 
is believed to be essential for a functional centromere. 
Thus, loss of DNA methylation altering this configuration 
can result in kinetochore dysfunction so losing the 
connection between chromosomes and the mitotic spindle 
an event known to cause chromosome missegregation 
and aneuploidy [33]. Imbalance in cytosine methylation 
(hypomethylation) and deregulation of DNA methyl-
transferases, are recurrent in human sporadic cancers 
and it was reported that they could be involved in the 
acquisition of chromosomal instability [34]. In a recent 
work, we demonstrated that DNA hypomethylation 
caused by DNMT1 post-transcriptional silencing induced 
aneuploidy in cells lacking p14ARF [14]. Here, we treated 
cells with low doses of DAC (2µM and 5 µM) in order 
to induce DNA hypomethylation without interfering with 
cell viability and we determined that DAC induces loss of 
DNA methylation at the centromere/pericentromere region 
resulting in mitotic defects (i.e. lagging chromosomes and 
micronuclei) that in turn underlie aneuploidy as suggested 
by the increase number of aneuploidy cells that raised 
up to 25-30% after DAC treatment. DAC acts through 
the formation of covalent adducts DNMT1-DAC-DNA 
leading to two consequences: the decrease of DNMT1 
into the cell and CpG hypomethylation [28]. Cells exposed 
Figure 8: DAC induces mitotic delay and chromosomal defects. Frame collection of DAC-treated cells progressing in mitosis 
obtained by time-lapse imaging. The DAC treatment (B) results in a delay of the anaphase onset for more than 40 min compared to the 
untreated control (normal mitosis in A). Images were acquired with phase contrast and GFP fluorescent filter. Scale bar represent 50μm.
Table1: Quantification of segregation defects. 
In the table are summarized the percentages of Lagging 
Chromosomes (LC) and Micronuclei (MN) observed 
durng time lapse analysis (Figure 8).
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to this drug for either a short (72 hours) or a long (1-2 
weeks) period of time became aneuploid. This condition 
was alleviated when cells were released in drug-free 
medium for additional two weeks. The decrease in DNA 
methylation was assessed by slot blot assay that evaluates 
the global degree of DNA methylation and by Methylation 
Specific PCR. Both strategies confirmed that low doses of 
DAC induce not only a global reduction in 5mC levels, 
but also the specific methylation loss of the CHFR gene 
promoter. Interestingly, the reduction in global DNA 
methylation was associated with a significant change of 
the 5mC pattern along mitotic chromosomes in that the 
presence of 5mC was detected in only one of the two sister 
chromatids after 48 hours of DAC treatment. This finding 
is in agreement with the semiconservative replication of 
the DNA in that after two cell divisions, one chromatid 
is originated by the unmethylated DNA strands resulting 
from the passive loss of DNA methylation induced by 
DAC. The other chromatid, instead, retains the original 
methylated strand. Our results also confirmed the HCT116 
cell cycle duration of about 24 hours. 
We hypothesize that DNA hypomethylation is 
directly responsible for the aneuploidy we observed. 
Our working model is supported by our time-lapse 
video-microscopy where we observed several mitotic 
alterations: mitotic delay, lagging chromosomes and 
micronuclei generation, all of them recognized as a cause 
of aneuploidy. 
Moreover, we observed the RR chromosomes 
that are characterized by the lack of the centromere and 
appear as two single chromatids close to each other. 
These RR chromosomes are not a consequence of 
premature separation of the sister chromatids since not 
all the chromatids in a metaphase appeared separated. 
Instead they appear to be the consequence of the loss of 
DNA methylation at the pericentromeric region of these 
chromosomes that affects the centromere organization. 
Although we cannot exclude that DNA 
hypomethylation might also affect genes involved in 
chromosome dynamics leading to destabilization of 
chromosome cohesion and segregation, our results 
suggest that the altered DNA methylation pattern could 
compromise the functionality of the centromere and 
consequently the correct chromosome segregation. 
Finally, our results point at DNA hypomethylation 
as a novel mechanism underlying aneuploidy and further 
studies should be aimed to evaluate the integrity and 
functionality of centromeres and kinetochores in cells 
undergoing DNA methylation loss.
MATERIALS AND METHODS
Cell culture
 Human colon cancer HCT-116 cells, characterized 
by a chromosome number of 45, were cultured in DMEM 
medium supplemented with 10% foetal calf serum, 100 U/
ml penicillin, 100 μg/ml Streptomycin and 1 mM Sodium 
Pyruvate (all from Gibco, Life Technology, Italy). Cells 
were grown at 37°C in a 4% CO2 humidified atmosphere 
and treated with 1, 2 and 5 μM of DAC (SIGMA-Aldrich, 
Italy) 24h after plating. Fresh medium supplemented with 
DAC was replaced every 24/36h. Assays were conducted 
on extracts harvested 1, 2 and 3 days or 1 week after the 
beginning of DAC treatment.
Evaluation of cell viability by the MTT assay.
Cell viability was assayed by using 
[3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium 
bromide] (MTT, SIGMA-Aldrich, Italy). Cells were 
seeded in a 96-well plate at a density of 103 cells/well in 
200μl of culture medium with only vehicle or DAC at 
different concentrations. Cells were incubated at 37°C 
in a humidified incubator at 5% CO2. Additionally, six 
wells were left empty for cell-free background reference. 
The medium was refreshed with a solution containing 
180μl medium plus 20μl of 5mg/ml MTT stock solution 
in PBS to each well (0.5 mg/ml final concentration). 
The microplate was incubated for 4h at 37°C, 5% CO2. 
The plate was centrifuged at 1000 rpm for 10 min and 
the medium totally removed from each wells followed 
by the addition of 100μl of DMSO to solubilise the MTT 
formazan. The absorbance of each well was measured at 
570nm on a multiplate reader (GloMax®-Multi Detection 
System, Promega, Italy) and the data saved as text file and 
imported into the statistical software Origin-Pro 8.5.1. 
(OriginLab Corporation) for processing. The percentage 
of viable cells was measured as follows:
Cell viability by Acridine Orange/Ethidium 
Bromide (AO/EB) Staining
A mixture of Acridine Orange was used for live cell 
indentification and Ethidium Bromide for discrimination 
between live and dead mammalian cells on the basis of 
membrane integrity. Cells were seeded in a 96-well plate 
at a density of 103 cells/well in 200μl of culture medium 
with only vehicle or DAC at different concentrations and 
times and incubated at 37°C, in a humidified incubator 
at 5% CO2. For the analysis, the medium was removed 
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and 20μl of the Acridine Orange (100μg/ml), Ethidium 
Bromide (100μg/ml) mixture (1:1, v/v) was added into 
each well and incubated for 20 seconds. The mixture 
was then removed and cells observed with fluorescent 
microscopy 
Cytofluorimetric analysis
HCT-116 cells were grown into complete medium 
(DMEM) and treated with DAC up to 48 hours. The 
DNA content was determined staining cells with 4μg/ml 
of Propidium Iodide (PI, SIGMA-Aldrich, Italy). The PI 
solution was prepared in PBS and it was supplemented 
with 40μg/ml RNase. Analysis of PI labelled cells was 
conducted as described previously [14] and samples were 
analysed on a FACSCanto (Becton Dickinson). 
Bivariate analysis to evaluate cell cycle progression/
duration where done by pulse labelling (1 h) cells with 
bromodeoxyuridine (BrdU 10μM). Analysis of BrdU 
labelled cells was conducted as described previously 
[14] [35]; briefly cells were fixed and stained with anti-
BrdUFITC antibody (biolegend USA), to detect BrdU 
positive cells (S-phase) and propidium iodide (PI) to 
assess DNA content and samples were analyzed on a 
FACSCanto (Becton Dickinson). Experiments were 
repeated at least twice and 10,000 events were analysed 
by using the softwares: FACSDiva (Becton Dickinson) 
and ModFit (Verity Software House, Inc.). 
Cytogenetics analysis
Cells were treated with 0.2μg/mL of colcemid 
(Demecolcine, SIGMA-Aldrich, Italy) for two hours, 
trypsinized and harvested by centrifugation at 1000 
rpm for 10 min. Cells were swollen by adding 75mM 
KCl dropwise and incubated at 37°C for 10 min, then 
centrifugated at 800 rpm for 10 min. The pellet was 
resuspended adding dropwise 5 mL of cold Carnoy’s 
fixative [methanol/acetic acid (3:1 v/v)] and incubated 
for 15 min on ice. After repeating the last step twice, 
cells were dropped onto iced slides. Chromosomes were 
stained either with Giemsa or with 1µg/mL of DAPI 
(4’,6-diamidino-2-phenylindole, SIGMA-Aldrich, Italy) 
and examined on a Zeiss Axioskop microscope equipped 
for fluorescence, images were captured with a CCD digital 
camera (AxioCam, Zeiss) and then transferred to Adobe 
PhotoShop. We evaluated at least 100 mitoses for each 
sample. The experiment was repeated twice.
Fluorescence Plus Giemsa Differential (FPG) 
Chromosome Staining. 
Asynchronous HCT116 cells to which BrdUrd 
(SIGMA-Aldrich, Italy) was added for 48 h were mitotic 
arrested with 0.2µg/ml of Demecolcine (SIGMA-Aldrich, 
Italy) for 1 h. Differential staining was conducted as 
previously described [30]; briefly, fixed slides were stained 
with Hoechst 33258 (0. 1 µg/ml) in PBS, placed under 
an UV lamp for 25 minutes, incubated in 2X SSC for 15 
minutes at 65°C and then stained with 3% Giemsa in a 
phosphate buffer (PBS) for 10 to 20 minutes. Picture of 
Differentially stained metaphases were saved in Adobe 
Photoshop.
Evaluation of 5mC content by 
Immunofluorescence microscopy 
DNA of fixed cells was denatured in 70% 
formamide/2X SSC (v/v) at 70°C for 5 min. The slides 
were then dehydrated in a series of 70, 80 and 100% 
cold ethanol and air dried. Samples were incubated 
in a blocking solution (3% bovine serum albumin, 
0.1% Tween-20/PBS) in coplin-jar for 1 hour. An anti- 
5-methylcytosine (5-mC) mouse monoclonal antibody 
(cloneD33, Epigentek, USA) was diluted 1:100 in 1% 
Tween-20/PBS,) and was added to the cells for 1 hour at 
37°C in a humidified chamber. The slides were washed 
with 0.05% Tween-20/PBS, 3 times for 10 min and 
incubated with FITC conjugated anti-mouse secondary 
antibody (diluted 1:1000 in 1% Tween-20/PBS) for 1 
hour at 37°C in a humidified chamber. Finally, cells were 
washed with 0.05% Tween-20/PBS 3 times 10 min each 
and nuclei were stained with 1µg/mL of DAPI. Fluorescent 
images of prophase nuclei were acquired using the Zeiss 
Axioskop microscope equipped for fluorescence. To 
estimate the fluorescent signal of each nucleus images 
were processed using the ImageJ software. The intensity 
of the 5-mC signal was calculated as integrated density 
and processed using the statistical software OriginPro 
8.5.1 (OriginLab Corporation) as corrected total cell 
fluorescence (CTCF) according to the following formula: 
CTCF = Integrated Density − (Area of selected cell × 
Mean fluorescence of background readings). The final 
value was normalized with DAPI signal. The same slides 
were used to evaluate the 5mC methylation pattern of 
metaphase chromosomes. For each condition tested, 
chromosomes of 50 metaphases were scanned along their 
longitudinal axis by using the RGB profile plot plugin of 
ImageJ that provided, for every rectangular selection, a 
two-dimensional graph of the intensities of pixels along 
a line and a plot list of the data, in which were reported 
the values of pixel intensity for each channel (blue, DAPI; 
green, 5-mC signal). That data were then processed with 
Origin-Pro 8.5.1 (OriginLab corporation) and graphed in 
two different colour lines for each fluorescent channel, 
where the x-axis represents the horizontal distance in 
microns through the chromosome and the y-axis the 
vertically averaged pixel intensity.
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Slot blot analysis
The DNA-slot blot analysis of 5-mC was performed 
as described in [36] with the following modifications. Non-
methylated DNA of Escherichia coli ET12567/pUZ8002 
[37] was used as negative control and methylated DNA 
of Escherichia coli Yale BW25113 [38] as positive 
control. Total genomic DNA was purified and 100 μg/25 
μL from each sample were denatured at 100°C for 5 
min and applied onto Hybond-N membrane (RPN203N, 
Amersham Biosciences) using the Hybrislot Manifold 
Apparatus (Whatman Biometra, Germany) under vacuum 
for 3 min. DNA was fixed to the membrane by exposing 
to UV light (70,000 μ joules/cm2) for 45 seconds using 
the Hoefer UVC 50 Crosslinker (Amersham Biosciences). 
The membrane was then incubated in 5% w/v no-fat dry 
milk prepared in TBST buffer (Tris Buffered Saline 0.05% 
Tween-20), for 1 hour at RT. This step was then followed 
by incubation with anti- 5-Methylcytosine Monoclonal 
Antibody (1:500, cloneD33, Epigentek, USA) for 1 hour 
at RT. The membrane was then washed 3 times with 
TBST for 10 min and incubated with an anti-mouse HRP 
conjugated secondary antibody diluted 1:2000 (Abcam, 
UK) for 1 hour at RT. After extensive washes in TBST 
(3 washes of 10 min each) the membrane was washed 
once in double distilled water and developed by enhanced 
chemiluminescence detection reagents (Pierce, Thermo 
Scientific). Images were acquired with the Chemidoc 
XSR Imaging System (BioRad). The amount of spotted 
DNA was detected by staining the membrane with 0.02% 
w/v methylene blue in 0.3 M sodium acetate (pH 5.2). 
Subsequently, washing in double distilled water was 
necessary to reduce the background noise. The relative 
5-mC optical density (OD) value was calculated with 
Quantity One 4.6.7 software (BioRad) and the amount of 
DNA was normalised against the wild type control.
Methylation Specific PCR (MSP)
Genomic DNA was extracted from DAC treated 
HCT-116 cells (1, 2 and 5µM) by using the All-Prep DNA/
RNA kit (Qiagen S.r.l.- Italy). 2µg of DNA in a volume 
of 20µl were converted by Epitect Bisulfite kit (Qiagen 
S.r.l.- Italy). Methylation-specific PCR amplification was 
carried out using oligonucleotide primers which were 
designed to anneal specifically to either methylated or 
unmethylated DNA after sodium bisulfite conversion as 
described above. The oligonucleotides used in this study 
were the following: Methylated DNA-specific primers 
were MCHFR-forward (5’-ATATAATATGGCGTCGATC) 
and MCHFR reverse (5’-TCAACTAATCCGCGAAACG). 
Unmethylated DNA-specific primers were UCHFR-
forward (5’-ATATAATATGGTGTTGATT) and UCHFR 
reverse (5’-TCAACTAATCCACAAAACA) [39]
The PCR reaction was performed using 100ng of 
DNA and the following reagents mix: 1x Buffer, 0,2 µM 
dNTP mix, 1,5 mM MgCl2, 0,5 µM Primer for, 0,5 µM 
Primer rev, 1,5U/µl Taq (Applied Biosystems, Thermo 
Fisher Scientific) PCR reaction consisted of a step at 95°C 
for 10min before of 45 cycles at 94°C for 1 min, 58°C for 
1min, 72°C for 1 min (MCHFR); 94°C for 1 min, 50°C 
for 1 min, 72°C for 1 min (UCHFR), followed by a final 
step at 72°C for 4 min. The resultant PCR products were 
resolved on a 1,8% agarose gel.
Reverse Transcription PCR (RT-PCR)
Primers to be used in Real time RT-PCR 
experiments were designed with Primer Express software 
(Applied Biosystems, Life Technologies) choosing 
amplicons of approximately 70-100 bp. The selected 
sequences were tested against public databases (BLAST) 
to confirm the identity of the genes. Total RNA was 
extracted from cells by using the “PureLink RNA mini 
kit ” (Ambion, Thermo Fisher Scientific) according 
to the manufacture’s instruction. RNA was reverse-
transcribed in a final volume of 20μL using the High 
Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Thermo Fisher Scientific) for 10 minutes 
at 25°C and 2 hours at 37°C. For each sample 50ng of 
cDNA, was analyzed by RT-PCR (95°C for 15 sec, 60°C 
for 60 sec repeated for 40 cycles). RT-PCR was done in 
a final volume of 20μl comprising 1x Master Mix SYBR 
Green (Applied Biosystems, Thermo Fisher Scientific) 
and 0,3 μM of forward and reverse primers for: GAPDH 
(Fw: 5’-CTCATG ACCACAGTCCATGCC-3’, Rev: 
5’-GCCATCCACA GTCTTCTGGGT-3’), CHFR (Fw: 
5’-CCTCAACAACCTCGTGGAAGCATAC -3’, Rev: 
5’-TCCTGGCATCCATACTTTGCACAT -3’).
Western blotting
Protein concentration was measured using the 
Bio-RadProtein Assay (Bio-Rad Laboratories). Proteins 
(40 μg) were separated by 4-12% Bolt bis-tris plus gels 
(Invitrogen, Thermo Fisher Scientific) and transferred 
to Hybond-C nitrocellulose membranes (Amersham 
Life Science) by electroblotting. The membranes were 
sequentially incubated with primary antibodies against 
CHFR (goat, Santa Cruz, 1:100), β-tubulin (mouse, 
SIGMA, 1:5000) and HRP-conjugated mouse (Pierce 
Thermo Fisher Scientific, 1:5000) or goat (ab97110, 
Abcam, 1:2000) as secondary antibodies. The target 
protein was detected with enhanced chemiluminescence 
Western blotting detection reagents (Pierce, Thermo Fisher 
Scientific). 
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Live imaging of cell division by time lapse video-
microscopy
HCT-116 cells expressing H2B-GFP were seeded 
in 25 cm2 flasks and treated with DAC as reported above 
and cultured in 6 mL of complete DMEM medium 
(Gibco) 24 h before Time-Lapse analysis, the medium 
was replaced with supplemented HEPES no phenol red 
DMEM (Gibco, Life Technology, Italy). Fluorescent and 
phase contrast images were automatically acquired every 
10-60 sec over a period of 1-4 h using the Epifluorescence 
inverted microscope Axio Observer D1 (Carl Zeiss). The 
microscope was controlled in an automated manner using 
the Axio-Vision40 V 4.8.2.0 software and housed in a 
home-made box to maintain a constant temperature of 
37°C. Fluorescence and differential interference constrast 
images were obtained. When necessary, manual focusing 
was performed every 20 min using the fluorescence 
channel. Time-lapse images were processed in Adobe 
Photoshop CS5 indicating the movie progression time in 
minutes.
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